Trial · NCT07891871
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
NCT07891871, Not yet recruiting, The Royal Wolverhampton Hospitals NHS Trust
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab. Trials, record NCT07891871. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07891871
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
- NCT number
- NCT07891871
- Status
- Not yet recruiting
- Enrollment
- 400 participants, estimated
- Lead sponsor
- The Royal Wolverhampton Hospitals NHS Trust
- Conditions
- Myeloma Multiple
- First posted
- 2026-10-23
- Last updated
- 2026-10-23
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of early severe treatment-related toxicity during step-up dosing | Time Period between 2024-2028 | Incidence of early severe treatment-related toxicity during step-up dosing, defined as: * Grade ≥3 CRS and/or ICANS, and/or * Unplanned hospital admission during step-up phase |
| Primary | Incidence of serious infection during treatment | Time Period between 2024-2028 | Incidence of serious infection during treatment, defined as: • Infection requiring hospital admission, ICU admission, or resulting in death |
| Secondary | Supportive care and infection-related management | Time Period between 2024-2028 | • Utilisation of immunoglobulin replacement therapy (IVIG/SCIG), including initiation, duration, and treatment intensity |
| Secondary | Subgroup and implementation variation analyses | Time Period between 2024-2028 | Associations between outcomes and: * Renal impairment * Prior BCMA-directed therapy exposure and refractoriness * Prior immunomodulatory (pomalidomide) refractoriness * Hospital type (tertiary centre vs district general hospital) * Socioeconomic deprivation index * Age and frailty (using simplified IMWG frailty score) * Ethnicity * Subsequent lines of therapy, including use of other bispecific antibodies |
| Secondary | Disease response and survival outcomes | Time Period between 2024-2028 | a. Overall Response Rate (ORR) • Proportion of participants achieving a partial response or better, including VGPR and complete response (CR), according to standard disease response criteria. |
| Secondary | Disease response and survival outcomes | Time Period between 2024-2028 | b: Progression-Free Survival (PFS) • Time from initiation of treatment to disease progression or death from any cause. |
| Secondary | Disease response and survival outcomes | Time Period between 2024-2028 | c: Progression-Free Survival 2 (PFS2) • Time from initiation of treatment to second disease progression or death from any cause. |
| Secondary | Disease response and survival outcomes | Time Period between 2024-2028 | d: Overall Survival (OS) • Time from initiation of treatment to death from any cause. |
| Secondary | Healthcare resource utilisation | Time Period between 2024-2028 | a: Hospitalisation Rate • Proportion of participants requiring hospital admission during step-up dosing and the early treatment period. |
| Secondary | Healthcare resource utilisation | Time Period between 2024-2028 | b: Length of Hospital Stay • Total number of inpatient bed-days per participant during the study period. |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07891871
GET https://conductscience.org/api/trials/v1/NCT07891871/registered